14507-51-8 Usage
Description
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is a synthetic steroid compound with the molecular formula C22H30O2. It belongs to the progestin group of hormones and exhibits a range of biological activities, including progestogenic, antiestrogenic, and antigonadotropic effects. 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) plays a crucial role in various medical applications due to its ability to interact with the progesterone receptor.
Uses
Used in Hormonal Contraceptives:
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is used as a progestin in the development of hormonal contraceptives. It helps prevent ovulation and alters the cervical mucus and endometrial lining, thereby reducing the chances of pregnancy.
Used in Hormone Replacement Therapy:
In hormone replacement therapy, 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is utilized to alleviate symptoms of menopause by providing the necessary hormonal balance. It helps regulate the menstrual cycle and supports the maintenance of pregnancy.
Used in Treatment of Menstrual Disorders:
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is employed in the treatment of menstrual disorders, such as dysmenorrhea and menorrhagia, by regulating the hormonal levels and reducing excessive bleeding.
Used in Endometriosis Treatment:
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is used in the treatment of endometriosis, a condition where the endometrial tissue grows outside the uterus. It helps reduce the size and growth of endometrial lesions and alleviates associated pain and discomfort.
Used in Cancer Therapy:
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is utilized in the treatment of certain types of cancer, particularly hormone-sensitive tumors. Its antiestrogenic and antigonadotropic effects help inhibit the growth and progression of cancer cells.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is used as an active pharmaceutical ingredient in the formulation of various hormonal medications, including contraceptives, hormone replacement therapies, and treatments for menstrual disorders and endometriosis.
Used in Research and Development:
18,19-Dinorpregna-2,5(10)-dien-20-yn-17-ol,13-ethyl-3-methoxy-, (17a)(9CI) is also used in research and development for understanding the mechanisms of action of progestins and their potential applications in treating various medical conditions. It aids scientists in developing new drugs and therapies based on the knowledge of its biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 14507-51-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,5,0 and 7 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 14507-51:
(7*1)+(6*4)+(5*5)+(4*0)+(3*7)+(2*5)+(1*1)=88
88 % 10 = 8
So 14507-51-8 is a valid CAS Registry Number.
14507-51-8Relevant articles and documents
Preparation method of levonorgestrel
-
Paragraph 0025-0026; 0028-0029; 0031-0032, (2020/09/20)
The invention discloses a preparation method of levonorgestrel, and belongs to the technical field of medicine preparation and processing. According to the method, 18-methylestra-2,5(10)-diene-3-methoxy-17-ketone is used as an initial raw material, and the levonorgestrel disclosed by the invention is prepared by virtue of two steps of ethynylation and hydrolysis. According to the preparation method of the levonorgestrel, the defects of a traditional process are overcome and reaction conditions are mild; the method is high in overall conversion rate, easy and convenient to operate, suitable forindustrial production and wide in market prospect.
AN IMPROVED PROCESS FOR PREPARATION OF LEVONORGESTREL
-
Page/Page column 9, (2012/09/10)
The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13 β-ethyl-3-methoxy-17α-ethynyl-gona-2,5(10)-dien-17β- o1 (2) with an acid in aprotic solvent. The present invention also provides a novel process for purification of crude levonorgestrel (3) by recrystallization from N,N-dimethyl formamide- water; methanol-water mixture.
Synthesis of 13-alkyl-gon-4-ones
-
, (2008/06/13)
The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
